Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y.
Qin Y, et al. Among authors: li y.
BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9.
BMC Cancer. 2024.
PMID: 38267866
Free PMC article.
Clinical Trial.